ESP Block for Breast Malignancy Surgery

Completed

• Conditions: Malignant neoplasm of breast, (2) ICD-10 Condition: O||Medical and Surgical,

• Registration Number: CTRI/2021/09/036782
• Lead Sponsor: BARC Hospital

Brief Summary

Prospective Randomised  Comparative Double blind study evaluating analgesic efficacy of 0.25% Bupivacaine vs 0.25% Bupivacaine with 0.5ug/kg Dexmedetomidine via USG guided ESPB for post operative pain relief of Breast malignancy surgery.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-10
• Study Completion: 2022-08-24
• Last Update Posted: 2022-08-30

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 52

Inclusion Criteria

• i.Adult female patients (age: 18-65yrs).
• ii.Patients with ASA physical status I and II.
• iii.Patients undergoing breast malignancy surgery.

Exclusion Criteria

• i.Patients refusal.
• ii.Patients with allergy to study drugs.
• iii.Patients with heart block and betablockers.
• iv.Heart rate <50bpm v.Pregnancy.
• vi.Patients with contraindications to peripheral nerve blocks like bleeding diathesis, localized skin infections and coagulopathy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Post operative pain	1,2,6,12 hrs

Secondary Outcome Measures

Name	Time	Method
PONV	within 24hrs postop.

Trial Locations

Locations (1)

BARC HOSPITAL; 🇮🇳 (Suburban), MAHARASHTRA, India

BARC HOSPITAL

🇮🇳(Suburban), MAHARASHTRA, India

Dr Pritee Bhirud

Principal investigator

9820669549

priteehb@barc.gov.in